Technology: CTP
Long-acting Enbrel (TNFR-FC) for treatment of autoimmune diseases by acting as a TNF inhibitor
Long-acting Enbrel (TNFR-FC) for treatment of autoimmune diseases by acting as a TNF inhibitor
Long-acting GCSF for enhancing neutrophils and monocytes after chemotherapy, intended to replace the Filgrastim daily treatment
Long-acting coagulation factor IX as a replacement therapy for Hemophilia B patients
Long-acting Oxyntomodulin for the treatment of obesity and diabetes, Phase 1 clinical trial was completed successfully
Long-acting Erythropoietin (EPO) for treatment of severe anemia in patients with chronic kidney disease and other hematologic disorders
Long-acting GLP-1 for the treatment of diabetes
Long-acting IFNβ for the treatment of MS-Multiple Sclerosis
Long-acting ApoA1 for the treatment of atherosclerosis
Long-acting Mutated growth hormone for treatment of acromegaly. Weekly dose to replace current daily treatment
Long-acting Insulin like growth factor for SPIGF1D- a form a dwarfism caused by insensitivity to hGH
Long-acting Glucagon like peptide-2 for treatment of short bowl syndrome
Parathyroid hormone for treatment of hypoparathyroidism. Weekly dose instead of a daily dose